New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors

Hear from experts about the emerging clinical trial data on the use of PI3K inhibitors to treat follicular lymphoma in the frontline and relapsed settings and the best practices for selecting candidates for PI3K therapies for selecting appropriate therapies and for managing adverse events. Review their insights in dowloadable slides and an on-demand webcast.

Share

Program Content

No activities added yet

Activities

Treatment landscape in R/R FL
Overview of the Current Treatment Landscape for Relapsed and Refractory Follicular Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

Clinical Data in R/R FL
Existing and Emerging Clinical Data of Available PI3K Inhibitors Used for the Treatment of R/R FL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

Role of PI3Ki in FL
Future Directions: The Evolving Role of PI3K Inhibitors for Patients With FL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

<i>EP</i>: PI3K Inhibitors in FL
ExpressPoints: New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2021

Expires: June 17, 2022

Faculty

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Nathan H. Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

TG Therapeutics